<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04659863</url>
  </required_header>
  <id_info>
    <org_study_id>CKJX839C12302</org_study_id>
    <secondary_id>2020-002755-38</secondary_id>
    <nct_id>NCT04659863</nct_id>
  </id_info>
  <brief_title>Study to Evaluate Efficacy and Safety of Inclisiran in Adolescents With Homozygous Familial Hypercholesterolemia</brief_title>
  <acronym>ORION-13</acronym>
  <official_title>Two Part (Double-blind Inclisiran Versus Placebo [Year 1] Followed by Open-label Inclisiran [Year 2]) Randomized Multicenter Study to Evaluate Safety, Tolerability, and Efficacy of Inclisiran in Adolescents (12 to Less Than 18 Years) With Homozygous Familial Hypercholesterolemia and Elevated LDL-cholesterol (ORION-13)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a pivotal phase III study designed to evaluate safety, tolerability, and efficacy of&#xD;
      inclisiran in adolescents with homozygous familial hypercholesterolemia (HoFH) and elevated&#xD;
      low density lipoprotein cholesterol (LDL-C).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a two-part (1 year double-blind inclisiran versus placebo / 1 year open-label&#xD;
      inclisiran) multicenter study designed to evaluate safety, tolerability, and efficacy of&#xD;
      inclisiran in adolescents with homozygous familial hypercholesterolemia (HoFH) and elevated&#xD;
      low density lipoprotein cholesterol (LDL-C) on stable standard of care background&#xD;
      lipid-lowering therapy. The primary objective is to evaluate the effect of inclisiran&#xD;
      compared to placebo in reducing LDL-C (percent change) at Day 330.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 16, 2021</start_date>
  <completion_date type="Anticipated">December 7, 2023</completion_date>
  <primary_completion_date type="Anticipated">November 14, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Parallel (Year 1) to single-group (Year 2)</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Masked (Year 1) to No Masking (Year 2)</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage (%) change in low-density lipoprotein cholesterol (LDL-C) from baseline to Day 330</measure>
    <time_frame>Baseline and Day 330</time_frame>
    <description>Evaluate the effect of inclisiran compared to placebo on reducing LDL-C [percent change] at Day 330 (Year 1)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time-adjusted percent change in LDL-C from baseline after Day 90 and up to Day 330</measure>
    <time_frame>Baseline, after Day 90 up to Day 330</time_frame>
    <description>Evaluate the effect of inclisiran compared to placebo on reducing LDL-C [time-adjusted percent change] over Year 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>% change and absolute change in LDL-C from baseline up to Day 720</measure>
    <time_frame>Baseline, up to Day 720</time_frame>
    <description>Evaluate the effect of inclisiran compared to placebo (for Year 1) and long-term (up to Day 720), on lowering LDL-C over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>% change and absolute change in other lipoprotein and lipid parameters from baseline up to Day 720</measure>
    <time_frame>Baselne, up to Day 720</time_frame>
    <description>Evaluate the effect of inclisiran compared to placebo (up to Day 330) and long-term (up to Day 720), on lowering apolipoprotein B (Apo B), lipoprotein (a) [Lp(a)], non-high density lipoprotein cholesterol (non-HDL-C), total cholesterol, triglycerides, high density lipoprotein cholesterol (HDL-C), very low density lipoprotein cholesterol (VLDL-C), apolipoprotein A1 (Apo A1) over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>% change and absolute change in proprotein convertase subtilisin/kexin type 9 (PCSK9) from baseline up to Day 720</measure>
    <time_frame>Baseline, up to Day 720</time_frame>
    <description>Evaluate the effect of inclisiran compared to placebo (up to Day 330) and long-term (up to Day 720), on lowering PCSK9 over time</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Familial Hypercholesterolemia - Homozygous</condition>
  <arm_group>
    <arm_group_label>Inclisiran</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Year 1 - inclisiran sodium 300 mg subcutaneous injection (given at Days 1, 90, and 270) Day 360 only - placebo subcutaneous injection Year 2 - inclisiran sodium 300 mg subcutaneous injection (given at Days 450 and 630)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Year 1 - placebo subcutaneous injection (given at Days 1, 90 and 270) Year 2 - inclisiran sodium 300 mg subcutaneous injection (given at Days 360, 450, and 630)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Inclisiran</intervention_name>
    <description>Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL solution for subcutaneous injection</description>
    <arm_group_label>Inclisiran</arm_group_label>
    <other_name>KJX839</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Sterile normal saline (0.9% sodium chloride in water for injection) for subcutaneous injection</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Saline solution</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Homozygous Familial Hypercholesterolemia (HoFH) diagnosed by genetic confirmation&#xD;
&#xD;
          -  Fasting LDL-C &gt;130 mg/dL (3.4 mmol/L) at screening&#xD;
&#xD;
          -  On maximally tolerated dose of statin (investigator's discretion) with or without&#xD;
             other lipid-lowering therapy; stable for â‰¥ 30 days before screening&#xD;
&#xD;
          -  Estimated glomerular filtration rate (eGFR) &gt;30 mL/min/1.73 m2 at screening&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Documented evidence of a null (negative) mutation in both LDLR alleles&#xD;
&#xD;
          -  Heterozygous familial hypercholesterolemia (HeFH)&#xD;
&#xD;
          -  Active liver disease&#xD;
&#xD;
          -  Secondary hypercholesterolemia, e.g. hypothyroidism or nephrotic syndrome&#xD;
&#xD;
          -  Major adverse cardiovascular events within 1 month prior to randomization&#xD;
&#xD;
          -  Previous treatment with monoclonal antibodies directed towards PCSK9 (within 90 days&#xD;
             of screening)&#xD;
&#xD;
          -  Treatment with mipomersen or lomitapide (within 5 months of screening)&#xD;
&#xD;
          -  Recent and/or planned use of other investigational medicinal products or devices&#xD;
&#xD;
        Other protocol-defined inclusion/exclusion criteria may apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>1-888-669-6682</phone>
    <email>novartis.email@novartis.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>+41613241111</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Excel Medical Clinical Trials LLC</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33434</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>561-756-8206</phone>
      <email>sjbaum@fpim.org</email>
    </contact>
    <investigator>
      <last_name>Seth Baum, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Quebec</city>
        <zip>G1V 4W2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bron Cedex</city>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ioannina</city>
        <state>GR</state>
        <zip>455 00</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Metropolitan Hospital</name>
      <address>
        <city>Athens</city>
        <zip>18547</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Genovefa Kolovou, MD</last_name>
      <phone>+30 210 4807139</phone>
      <email>genovefa@kolovou.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ashrafieh</city>
        <zip>166830</zip>
        <country>Lebanon</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015 GD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ljubljana</city>
        <zip>1000</zip>
        <country>Slovenia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Geneve 14</city>
        <zip>1211</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Istanbul</city>
        <state>TUR</state>
        <zip>34098</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Izmir</city>
        <zip>35040</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>France</country>
    <country>Greece</country>
    <country>Lebanon</country>
    <country>Netherlands</country>
    <country>Slovenia</country>
    <country>Switzerland</country>
    <country>Turkey</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>December 2, 2020</study_first_submitted>
  <study_first_submitted_qc>December 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 9, 2020</study_first_posted>
  <last_update_submitted>October 15, 2021</last_update_submitted>
  <last_update_submitted_qc>October 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Homozygous familial hypercholesterolemia (HoFH)</keyword>
  <keyword>LDL-cholesterol (LDL-C)</keyword>
  <keyword>adolescents</keyword>
  <keyword>pediatric</keyword>
  <keyword>small interfering ribonucleic acid (siRNA)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperlipoproteinemia Type II</mesh_term>
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.&#xD;
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

